Breathe Well Live Well
|
Glaxo's Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Yahoo News Several companies including Teva Pharmaceutical Industries Limited TEVA and AstraZeneca plc AZN are looking to bring their anti IL-5 antibodies to the market for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD). |
View full post on asthma – Google News
BioPharma Dive |
Glaxos Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Zacks.com In the U.S., the drug is approved for both COPD and asthma. We note that Glaxo has a collaboration agreement with Theravance for Relvar/Breo Ellipta and Anoro Ellipta (COPD). Relvar/Breo Ellipta generated sales of £94 million in the first half of 2015. After bad news on Breo, Glaxo's monthly asthma drug wins an EU rec |
View full post on asthma – Google News
PMLiVE |
CHMP backs GSK's asthma antibody and Novartis' heart failure drug
PMLiVE GlaxoSmithKline's mepolizumab for severe asthma and Novartis new' heart failure therapy Entresto have been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The panel issued positive opinions for the two drugs … |
View full post on asthma – Google News
Yahoo News |
EU regulator backs approval for GSK injectable asthma drug
Yahoo News The treatment could help boost GSK's respiratory drugs business as demand weakens for its asthma drug, Advair. A significant minority of asthma patients do not respond to regular inhalers such as Advair, Dulera and Flovent, creating what analysts … Glaxo asthma drug clears key hurdle in Europe CHMP Backs Mepolizumab for Severe Eosinophilic Asthma GlaxoSmithKline's asthma injection heads for EU approval |
View full post on asthma – Google News
|
BRIEF-GSK gets European regulators approval for biotech asthma drug
Reuters Sept 24 GlaxoSmithkline Plc. * Receives positive CHMP opinion in Europe for novel anti-IL5 biological nucala for treatment of patients with severe refractory eosinophilic asthma. * Decision is based on results from clinical study programme, which … |
View full post on asthma – Google News
Yahoo News |
Glaxo asthma drug clears key hurdle in Europe
MarketWatch LONDON–GlaxoSmithKline PLC's [GSK.LN] new severe-asthma medicine has received a positive opinion from the scientific committee of the European Medicines Agency for use in adults, clearing a key hurdle towards gaining marketing approval in Europe. EU regulator backs approval for GSK injectable asthma drug GlaxoSmithKline plc (ADR) To Lead Asthma Market GlaxoSmithKline's asthma injection heads for EU approval |
View full post on asthma – Google News
Reuters |
EU regulator backs approval for GSK injectable asthma drug
Reuters GlaxoSmithKline Plc said the European health regulator had recommended an approval for its injectable drug to treat asthma patients who don't respond well to traditional inhalers. The European Commission is expected to decide on a final approval for … Glaxo asthma drug clears key hurdle in Europe GlaxoSmithKline's asthma injection heads for EU approval Europe's CHMP give thumbs up to Glaxo's Nucala for severe asthma |
View full post on asthma – Google News
WFMZ Allentown |
Health Beat: New asthma drug stops attacks
WFMZ Allentown For some, inhalers and steroids don't work. Now, researchers at Washington University School of Medicine in St. Louis have found a new drug — Reslizumab — to prevent attacks from happening. It goes after the molecule that causes asthma. New Asthma Drug Stops Attacks |
View full post on asthma – Google News
In-Cyprus (press release) (subscription) (blog) |
GSK: New biotech asthma drug
In-Cyprus (press release) (subscription) (blog) GlaxoSmithKline may get a green light from European regulators as early as this week for a new biotech medicine to treat severe asthma, boosting prospects for its struggling respiratory business. A recommendation from the European Medicines Agency … |
View full post on asthma – Google News
|
GSK may get EU green light for new biotech asthma drug this week
Reuters Nucala is first in new drug class for severe asthma. * EMA weighs verdict on Nucala at Sept. 21-24 meeting. By Ben Hirschler. LONDON, Sept 23 (Reuters) – GlaxoSmithKline may get a green light from European regulators as early as this week for a new … |
View full post on asthma – Google News